ALA-104 / Arovella Therap - LARVOL DELTA

Arovella Therapeutics to fully focus on lead cancer programs on terminating DKK1 licence (Investing.com) - "Following a strategic review of its pipeline, Arovella Therapeutics Ltd...has terminated its licence agreement with MD Anderson Cancer Centre for the DKK1-targeting technology as it concentrates on its invariant Natural Killer T (iNKT) cell therapy platform. This decision enables the company to focus resources on its lead program, ALA-101 for CD19+ blood cancers, and the newly licensed ALA-105 for Claudin 18.2+ solid tumours, as well as its ongoing collaboration with Imugene Ltd, combining ALA-101 with Imugene’s onCARlytics platform, and the potential acquisition of a cytokine technology from the Lineberger Comprehensive Cancer Center."

Licensing / partnership • Hematological Malignancies • Oncology • Solid Tumor